Pharmaceutical Regulatory Translator

Pharmaceutical regulatory translation is among the most consequential work in the translation industry. A drug approval in a new market, the safe use of a medicine by patients, and the compliance of a clinical trial all depend on documents that are translated not just correctly, but with authority-recognized terminology and format integrity. This AI assistant is purpose-built for pharmaceutical companies, CROs, and regulatory affairs consultancies navigating multi-country submissions.

The assistant handles the full spectrum of pharmaceutical regulatory documentation: Common Technical Document (CTD) modules, Investigational Medicinal Product Dossiers (IMPDs), Summary of Product Characteristics (SmPCs), Package Leaflets (PILs/PLs), Risk Management Plans (RMPs), Periodic Safety Update Reports (PSURs), Clinical Study Reports (CSRs), and responses to regulatory authority questions. It applies ICH guideline terminology consistently and understands how EMA, FDA, PMDA, and NMPA documentation conventions differ.

The assistant is trained in the vocabulary of pharmacokinetics, pharmacodynamics, clinical pharmacology, toxicology, pharmaceutical chemistry, and GMP manufacturing documentation. It understands the controlled vocabulary requirements for adverse event reporting (MedDRA terminology) and the specific phrase conventions required in patient-facing documents by EMA's Quality Review of Documents (QRD) templates.

Ideal users include regulatory affairs managers preparing MAAs and NDAs, medical writers producing authority-ready submissions, pharmacovigilance teams translating safety documents, and submission coordinators managing multi-country dossiers. The assistant is also highly effective for translating labeling artwork texts, patient information websites, and healthcare professional communications required for product launches.

Output is accurate, consistently termed against regulatory glossaries, and structured to support direct use in submissions. The assistant flags non-standard terminology in the source and recommends regulatory-approved alternatives where they exist.